Safety and Efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: a systematic review and meta‐analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and Efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: a systematic review and meta‐analysis

Published:2021-01-19 Issue:4 Volume:10 Page:1222-1239
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Geng Yichao¹^ORCID,Zhang Qiuning²³,Feng Shuangwu¹^ORCID,Li Chengcheng¹^ORCID,Wang Lina¹,Zhao Xueshan¹,Yang Zhen⁴,Li Zheng²³,Luo Hongtao²³,Liu Ruifeng²³,Lu Bing⁵⁶,Wang Xiaohu¹²³^ORCID

Affiliation:

1. The First School of Clinical Medicine Lanzhou University Lanzhou China

2. Institute of Modern Physics Chinese Academy of Sciences Lanzhou China

3. Lanzhou Heavy Ion Hospital Lanzhou China

4. Basic Medical College Lanzhou University Lanzhou China

5. Department of Oncology The Affiliated Hospital of Guizhou Medical University Guiyang China

6. Department of Oncology Guizhou Cancer Hospital Guiyang China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3718

Reference62 articles.

1. Cancer statistics, 2020

2. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China

3. Cancer immunotherapy using checkpoint blockade

4. Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials

5. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy and Radiotherapy for Older Patients with Locally Advanced Non-Metastatic Non-Small-Cell Lung Cancer Who Are Not Candidates for or Decline Surgery and Chemotherapy: A Practical Proposal by the International Geriatric Radiotherapy Group;Cancers;2024-09-09

2. Impact of thoracic radiotherapy on first‐line treatment outcomes in ES‐SCLC patients;Cancer Medicine;2024-09

3. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy;Journal of Translational Medicine;2024-08-09

4. An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade;Journal for ImmunoTherapy of Cancer;2024-08

5. A future directions of renal cell carcinoma treatment: combination of immune checkpoint inhibition and carbon ion radiotherapy;Frontiers in Immunology;2024-07-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3